BioNTech SE Share Price

Equities

BNTX

US09075V1026

Biotechnology & Medical Research

Market Closed - Nasdaq 01:30:00 25/05/2024 am IST 5-day change 1st Jan Change
96.95 USD -2.07% Intraday chart for BioNTech SE +7.00% -8.14%

Financials

Sales 2024 * 2.8B 3.03B 252B Sales 2025 * 2.77B 3B 249B Capitalization 21.55B 23.38B 1,942B
Net income 2024 * -435M -472M -39.19B Net income 2025 * -508M -551M -45.76B EV / Sales 2024 * 2.42 x
Net cash position 2024 * 14.78B 16.02B 1,331B Net cash position 2025 * 13.76B 14.92B 1,240B EV / Sales 2025 * 2.82 x
P/E ratio 2024 *
-49.5 x
P/E ratio 2025 *
-44.3 x
Employees 6,133
Yield 2024 *
-
Yield 2025 *
-
Free-Float 86.48%
More Fundamentals * Assessed data
Dynamic Chart
1 day-2.07%
1 week+7.00%
Current month+9.15%
1 month+10.06%
3 months+3.17%
6 months-1.90%
Current year-8.14%
More quotes
1 week
90.24
Extreme 90.24
102.66
1 month
86.36
Extreme 86.36
102.66
Current year
85.21
Extreme 85.2129
114.70
1 year
85.21
Extreme 85.2129
125.83
3 years
85.21
Extreme 85.2129
464.00
5 years
12.53
Extreme 12.525
464.00
10 years
12.53
Extreme 12.525
464.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 02/08/02
Founder 57 02/08/02
Director of Finance/CFO 60 01/21/01
Members of the board TitleAgeSince
Director/Board Member 69 01/22/01
Director/Board Member 67 02/08/02
Chairman 53 02/08/02
More insiders
Date Price Change Volume
24/24/24 96.95 -2.07% 1,245,252
23/24/23 99 -3.23% 1,553,710
22/24/22 102.3 +11.11% 3,753,038
21/24/21 92.07 -0.43% 609,315
20/24/20 92.47 +2.05% 340,966

Delayed Quote Nasdaq, May 25, 2024 at 01:30 am IST

More quotes
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
89.32 EUR
Average target price
104.7 EUR
Spread / Average Target
+17.22%
Consensus